US private equity firm AshHill Investments and Australian VC fund Trans Tasman Commercialisation Fund (TTCF) have invested $4m in London-based biotech company Heart Metabolics.
Renewable energy service will also receive future growth funding from the GP
Relationship is set to facilitate access to Pantheon's offering for French institutional investors
Deal follows the acquisition of the company's bank debt by Idea CCR II in December 2017
Newly appointed partner Richard Goldsack previously worked at Grant Thornton and EY